VERRICA PHARMACEUTICALS INC (VRCA)
US92511W1080 - Common Stock
We assign a fundamental rating of 2 out of 10 to VRCA. VRCA was compared to 193 industry peers in the Pharmaceuticals industry. VRCA has a bad profitability rating. Also its financial health evaluation is rather negative. VRCA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VRCA has reported negative net income.
VRCA had a negative operating cash flow in the past year.
In the past 5 years VRCA always reported negative net income.
VRCA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -167.14%, VRCA is doing worse than 88.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -167.14% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-60.22%
ROA(5y)-55.89%
ROE(3y)-169.25%
ROE(5y)-136.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VRCA's Gross Margin of 84.03% is amongst the best of the industry. VRCA outperforms 89.58% of its industry peers.
VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRCA has been increased compared to 1 year ago.
VRCA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VRCA has a worse debt to assets ratio.
2.2 Solvency
VRCA has an Altman-Z score of -10.69. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
VRCA's Altman-Z score of -10.69 is on the low side compared to the rest of the industry. VRCA is outperformed by 77.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.69 |
ROIC/WACCN/A
WACC10.61%
2.3 Liquidity
VRCA has a Current Ratio of 2.36. This indicates that VRCA is financially healthy and has no problem in meeting its short term obligations.
VRCA has a worse Current ratio (2.36) than 61.46% of its industry peers.
VRCA has a Quick Ratio of 2.23. This indicates that VRCA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VRCA (2.23) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.23 |
3. Growth
3.1 Past
VRCA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -276.00%.
The Revenue has grown by 61.57% in the past year. This is a very strong growth!
EPS 1Y (TTM)-276%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.17%
Revenue 1Y (TTM)61.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2744.51%
3.2 Future
VRCA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.62% yearly.
VRCA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 143.70% yearly.
EPS Next Y0.96%
EPS Next 2Y18.08%
EPS Next 3Y19.7%
EPS Next 5Y30.62%
Revenue Next Year395.82%
Revenue Next 2Y218.28%
Revenue Next 3Y167.81%
Revenue Next 5Y143.7%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VRCA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRCA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VRCA's earnings are expected to grow with 19.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.08%
EPS Next 3Y19.7%
5. Dividend
5.1 Amount
No dividends for VRCA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VERRICA PHARMACEUTICALS INC
NASDAQ:VRCA (11/4/2024, 8:00:02 PM)
After market: 1.15 -0.28 (-19.58%)1.43
-0.1 (-6.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap61.02M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -167.14% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.03% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-276%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y0.96%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)61.57%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y